Recruiting Clinical Trials
Study Title |
Condition |
Phase |
Location |
A 28-week, Randomized, Double-blind, Active Controlled, Multicenter Study to Evaluate the Efficacy of Subcutaneously Administered Secukinumab Compared to Ustekinumab in Adult Patients With Psoriatic Arthritis and Failure of TNFα- Inhibitor Treatment ... |
Psoriatic Arthritis |
Phase 3 |
|
An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously |
Relapsing Multiple Sclerosis (RMS) |
Phase 4 |
|
A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Patients With Macular Edema |
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion |
Phase 1 |
|
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in P ... |
Giant Cell Arteritis (GCA) |
Phase 3 |
|
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment |
Autoimmunity, Inflammation |
Phase 4 |
|
An Open-label, Single-arm, Active-treatment Study to Evaluate Efficacy and Safety of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Adult Onset Still's Disease (AOSD) |
Adult Onset Still's Disease |
Phase 3 |
|
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) |
Sjögren Syndrome |
Phase 2 |
|
A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer. |
Non Small Cell Lung Cancer |
Phase 1, Phase 2 |
|
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants |
Hepatic Impairment |
Phase 1 |
|
FocuS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD |
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases, Retinal Degeneration, Geographic Atrophy, Macular Atrophy |
Phase 1, Phase 2 |
|